Carcinoma, Non-Small-Cell Lung: all 6,641 studies

Page 15 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.

• A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyRecruitingNCT05338619Phase 2
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
• Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLCRecruitingNCT05332925
• A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid TumorRecruitingNCT05332574Phase 1/2
• Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer PatientsRecruitingNCT05319886
• Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingNCT05317858Phase 3
• Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2
• Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerRecruitingNCT05297734Not applicable
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingNCT05296564Phase 1/2
• Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLCRecruitingNCT05296278Phase 2
• Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIBRecruitingNCT05295212Phase 2
• Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung CancerRecruitingNCT05292521Not applicable
• Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingNCT05288205Phase 1/2
• MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLCRecruitingNCT05286957Phase 2
• Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsRecruitingNCT05283330Phase 1
• Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)RecruitingNCT05281406Phase 2
• Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLCRecruitingNCT05278052Phase 3
• Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLCRecruitingNCT05277844Phase 2
• A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1RecruitingNCT05276726Phase 1/2
• XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNot yet recruitingNCT05275374Phase 1/2
• TT-702 in Patients With Advanced Solid Tumours.RecruitingNCT05272709Phase 1/2
• First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsRecruitingNCT05271916Phase 1/2
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingNCT05267626Phase 1/2
• Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung CancerRecruitingNCT05267288Phase 2
• Biology of Young Lung Cancer Study: The YOUNG LUNG StudyRecruitingNCT05265429
• Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung CancerRecruitingNCT05260606
• CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal DiseaseRecruitingNCT05257967Not applicable
• Using ctDNA to Detect Minimal Residual Disease After Lung Cancer ResectionRecruitingNCT05254782
• KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLCRecruitingNCT05254184Phase 1
• Artificial Intelligence for Help Non-Small Cell Lung Cancer: Measure Cancer Biology and Treatment Response Via ImagingNot yet recruitingNCT05254132
• Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment FailureNot yet recruitingNCT05248022Not applicable
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionRecruitingNCT05245500Phase 1
• A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung CancerRecruitingNCT05242965Phase 2Results posted
• Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerRecruitingNCT05241028Phase 2
• GEMINI-NSCLC: NSCLC Biomarker StudyRecruitingNCT05236114
• PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05234307Phase 1
• AOH1996 for the Treatment of Refractory Solid TumorsRecruitingNCT05227326Phase 1
• ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)RecruitingNCT05221372
• Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLCNot yet recruitingNCT05218759Not applicable
• Primary Tumor Resection With EGFR TKI for Stage IV NSCLCRecruitingNCT05215548Phase 2
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1
• A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibNot yet recruitingNCT05204628Phase 3
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingNCT05194982Phase 1
• A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerNot yet recruitingNCT05186506Phase 2
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingNCT05176483Phase 1
• Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT05168566Phase 2
• The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung CancerNot yet recruitingNCT05167851Phase 2
• Pathological Response After Neoadjuvant Treatment on NSCLCRecruitingNCT05167487
• A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver MutationsRecruitingNCT05157776Phase 3
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Phase 1/2
• Copenhagen Master Observational TrialRecruitingNCT05145244
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerRecruitingNCT05142189Phase 1
• Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.RecruitingNCT05128630Phase 2
• Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLCRecruitingNCT05122806Not applicable
• A Study of NX-1607 in Adults With Advanced MalignanciesRecruitingNCT05107674Phase 1
• A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingNCT05104788Phase 2
• First-in-human Study of OVM-200 as a Therapeutic Cancer VaccineRecruitingNCT05104515Phase 1
• Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.RecruitingNCT05102110
• Survey of Brigatinib Used To Treat People With Non-Small Cell Lung CancerRecruitingNCT05100069
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other CancersRecruitingNCT05098132Phase 1/2
• Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)RecruitingNCT05094882
• A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT05085028Phase 3
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsRecruitingNCT05076760Phase 1
• A Study of FWD1509 in Adults With Non-Small Cell Lung CancerRecruitingNCT05068024Phase 1/2
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
• Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLCRecruitingNCT05060796Early Phase 1
• Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung CancerRecruitingNCT05059951
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruitingNCT05059444
• A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
• The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid TumorsRecruitingNCT05037825
• Osimertinib for Advanced EGFR-positive NSCLC PatientsRecruitingNCT05037331
• A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain MetastasesRecruitingNCT05033691Not applicable
• Dose-painting Radiation for LA-NSCLCRecruitingNCT05031533Not applicable
• Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2
• Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCRecruitingNCT05011487Phase 2
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingNCT05005403Phase 1
• Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05004974Phase 2
• AB122 Platform StudyRecruitingNCT04999761Phase 1
• A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid TumorsRecruitingNCT04996121Phase 1/2
• Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung CancerRecruitingNCT04992780Phase 2
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingRecruitingNCT04981119
• Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer PatientsRecruitingNCT04980716Phase 3
• Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung CancerRecruitingNCT04977791
• Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung CancerRecruitingNCT04973293Not applicable
• TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural MesotheliomaRecruitingNCT04969315Phase 1/2
• Using ctDNA to Determine Therapies for Lung CancerRecruitingNCT04966663Phase 2
• A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingNCT04951635Phase 3
• ROSE for Improved Molecular Marker Testing Via EBUSEnrolling by invitationNCT04945317Not applicable
• Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung FieldRecruitingNCT04944563Not applicable
• BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabRecruitingNCT04933903Phase 2
• Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Phase 1/2
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Phase 3
• Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative OptionRecruitingNCT04926584
• An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT04919616Early Phase 1
• Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung CancerRecruitingNCT04913311
• A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsRecruitingNCT04913285Phase 1
• Observational Study of Afatinib 30 mg DailyRecruitingNCT04909073
• Patient-centered, Optimal Integration of Survivorship and Palliative CareRecruitingNCT04900935Not applicable

← Carcinoma, Non-Small-Cell Lung overview